Global (United States, European Union and China) Measles Vaccine Market Research Report 2019-2025

2 Global Measles Vaccine Quarterly Market Size Analysis

• 2.1 Measles Vaccine Business Impact Assessment - COVID-19
  • 2.1.1 Global Measles Vaccine Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Measles Vaccine Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Measles Vaccine Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Measles Vaccine Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Measles Vaccine Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Measles Vaccine Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Measles Vaccine Market
• 3.5 Key Manufacturers Measles Vaccine Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Measles Vaccine Segments, By Type

• 4.1 Introduction
  • 1.4.1 Mumps Measles Rubella Vaccine, Live (MMR-II)
  • 1.4.2 Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
• 4.2 By Type, Global Measles Vaccine Market Size, 2019-2021
  • 4.2.1 By Type, Global Measles Vaccine Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Measles Vaccine Price, 2020-2021

5 Impact of Covid-19 on Measles Vaccine Segments, By Application

• 5.1 Overview
  • 5.5.1 Children
  • 5.5.2 Adults
• 5.2 By Application, Global Measles Vaccine Market Size, 2019-2021
  • 5.2.1 By Application, Global Measles Vaccine Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Measles Vaccine Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 GSK
  • 7.1.1 GSK Business Overview
  • 7.1.2 GSK Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.1.3 GSK Measles Vaccine Product Introduction
  • 7.1.4 GSK Response to COVID-19 and Related Developments
• 7.2 Sanofi-Pasteur
  • 7.2.1 Sanofi-Pasteur Business Overview
  • 7.2.2 Sanofi-Pasteur Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.2.3 Sanofi-Pasteur Measles Vaccine Product Introduction
  • 7.2.4 Sanofi-Pasteur Response to COVID-19 and Related Developments
• 7.3 Merck
  • 7.3.1 Merck Business Overview
  • 7.3.2 Merck Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.3.3 Merck Measles Vaccine Product Introduction
  • 7.3.4 Merck Response to COVID-19 and Related Developments
• 7.4 Novartis
  • 7.4.1 Novartis Business Overview
  • 7.4.2 Novartis Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.4.3 Novartis Measles Vaccine Product Introduction
  • 7.4.4 Novartis Response to COVID-19 and Related Developments
• 7.5 Pfizer
  • 7.5.1 Pfizer Business Overview
  • 7.5.2 Pfizer Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.5.3 Pfizer Measles Vaccine Product Introduction
  • 7.5.4 Pfizer Response to COVID-19 and Related Developments
• 7.6 Serum Institute of India
  • 7.6.1 Serum Institute of India Business Overview
  • 7.6.2 Serum Institute of India Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.6.3 Serum Institute of India Measles Vaccine Product Introduction
  • 7.6.4 Serum Institute of India Response to COVID-19 and Related Developments
• 7.7 China National Biotech Group
  • 7.7.1 China National Biotech Group Business Overview
  • 7.7.2 China National Biotech Group Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.7.3 China National Biotech Group Measles Vaccine Product Introduction
  • 7.7.4 China National Biotech Group Response to COVID-19 and Related Developments
• 7.8 Bavarian Nordic
  • 7.8.1 Bavarian Nordic Business Overview
  • 7.8.2 Bavarian Nordic Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.8.3 Bavarian Nordic Measles Vaccine Product Introduction
  • 7.8.4 Bavarian Nordic Response to COVID-19 and Related Developments
• 7.9 Emergent Biosolutions
  • 7.9.1 Emergent Biosolutions Business Overview
  • 7.9.2 Emergent Biosolutions Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.9.3 Emergent Biosolutions Measles Vaccine Product Introduction
  • 7.9.4 Emergent Biosolutions Response to COVID-19 and Related Developments
• 7.10 Medimmune
  • 7.10.1 Medimmune Business Overview
  • 7.10.2 Medimmune Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.10.3 Medimmune Measles Vaccine Product Introduction
  • 7.10.4 Medimmune Response to COVID-19 and Related Developments
• 7.11 Johnson & Johnson
  • 7.11.1 Johnson & Johnson Business Overview
  • 7.11.2 Johnson & Johnson Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.11.3 Johnson & Johnson Measles Vaccine Product Introduction
  • 7.11.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.12 CSL Limited
  • 7.12.1 CSL Limited Business Overview
  • 7.12.2 CSL Limited Measles Vaccine Quarterly Production and Revenue, 2020
  • 7.12.3 CSL Limited Measles Vaccine Product Introduction
  • 7.12.4 CSL Limited Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Measles Vaccine Supply Chain Analysis
  • 8.1.1 Measles Vaccine Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Measles Vaccine Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Measles Vaccine Distribution Channels
  • 8.2.2 Covid-19 Impact on Measles Vaccine Distribution Channels
  • 8.2.3 Measles Vaccine Distributors
• 8.3 Measles Vaccine Customers

9 Key Findings

10 Appendix

• 10.1 About Us